Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.76 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.44 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.44 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | ACACA | Q13085 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PLCG1 | P19174 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12152369 | 1.00 | MEN1 (0.76) | MEN1KMT2ARELAKDM4EMAPT | |
| SCHEMBL23484310 | 1.00 | MEN1 (0.76) | MEN1KMT2ARELAKDM4EMAPT | |
| SCHEMBL10049047 | 0.94 | KMT2A (0.67) | MEN1KMT2ARELAKDM4EMAPT | |
| SCHEMBL10017449 | 0.91 | MEN1 (0.63) | MEN1KMT2ARELAKDM4EMAPT | |
| SCHEMBL12152371 | 0.91 | MEN1 (0.63) | MEN1KMT2ARELAKDM4EMAPT | |
| SCHEMBL29524845 | 0.91 | MEN1 (0.63) | MEN1KMT2ARELAKDM4EMAPT | |
| SCHEMBL12152370 | 0.90 | MEN1 (0.61) | MEN1KMT2ARELAKDM4EMAPT | |
| SCHEMBL23105464 | 0.89 | MEN1 (0.66) | MEN1KMT2ARELAKDM4EMAPT | |
| Gamma Oryzanol SCHEMBL23105398 | 0.88 | MEN1 (0.60) | MEN1KMT2ARELAKDM4EMAPT | |
| Gamma Oryzanol SCHEMBL21235210 | 0.88 | MEN1 (0.60) | MEN1KMT2ARELAKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12385071-B2 | Methods for the production of ferulic acid | INVENTURE RENEWABLES, INC. (US) | 2025-08-12 | — | — | US | claimed |
| WO-2024243311-A1 | INSOLUBLE CORN FIBER COMPOSTION | CARGILL, INCORPORATED (US) | 2024-11-28 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-117070527-A | Application of rice gene HL6 in regulation and control of diterpene plant protection element content and enhancement of disease resistance | 华中农业大学 | 2023-11-17 | — | — | CN | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20230027119-A1 | METHODS FOR THE PRODUCTION OF FERULIC ACID | INVENTURE RENEWABLES INC (US) | 2023-01-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2021138549-A1 | METHODS FOR THE PRODUCTION OF FERULIC ACID | INVENTURE RENEWABLES, INC. (US) | 2021-07-08 | — | — | WO | claimed |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | NATURAL EXTRACTION SYS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | Natural Extraction Systems, LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-12385071-B2 | Methods for the production of ferulic acid | INVENTURE RENEWABLES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-12385071-B2 | Methods for the production of ferulic acid | INVENTURE RENEWABLES, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250228912-A1 | COMPOSITION AND METHODS OF TREATMENT FOR SKIN HEALTH AND SLEEP QUALITY USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Xygenyx Inc. | 2025-07-17 | — | — | US | disclosed |
| US-20250171465-A1 | AKT INHIBITORS | Stablix, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-20100056487-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | SATORI PHARMACEUTICALS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056487-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | SATORI PHARMACEUTICALS, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2008130449-A2 | MODULATORS OF AMYLOID-BETA PRODUCTION | SATORI PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20050043287-A1 | Composition comprising L-arginine as a muscle growth stimulant and use thereof | ALLEN ANN DE WEES (US) | 2005-02-24 | — | — | US | disclosed |
| US-6608109-B2 | Replacement for steroids and for stimulating an immune response; in a form which is palatable; acid pH less than 7.0; citric acid | ALLEN ANN DE WEES (US) | 2003-08-19 | — | — | US | disclosed |
| US-20030119888-A1 | COMPOSITION COMPRISING L-ARGININE AS A MUSCLE GROWTH STIMULANT AND USE THEREOF | ALLEN ANN DE WEES (US) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043287-A1 | Composition comprising L-arginine as a muscle growth stimulant and use thereof | ARG1, MUSK, ARG2 | MEN1 2948/4885KMT2A 3373/4885RELA 2014/4885 |
| US-20030119888-A1 | COMPOSITION COMPRISING L-ARGININE AS A MUSCLE GROWTH STIMULANT AND USE THEREOF | ARG1, MUSK, ARG2 | MEN1 2948/4885KMT2A 3373/4885RELA 2014/4885 |
| US-12409152-B2 | Compositions and methods related to dissolved oxides | PRKG2, PRKG1, CIT | MEN1 593/4885KMT2A 3932/4885RELA 2112/4885 |
| US-20250228912-A1 | COMPOSITION AND METHODS OF TREATMENT FOR SKIN HEALTH AND SLEEP QUALITY USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | COL2A1, COL1A1, IGFBP1 | MEN1 469/4885KMT2A 1975/4885RELA 3531/4885 |
| US-20250171465-A1 | AKT INHIBITORS | PIK3CA, PIK3CD, PIK3CG | MEN1 1778/4885KMT2A 1525/4885RELA 663/4885 |
| US-20260048025-A1 | COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES | SCO2, CNR2, CNR1 | MEN1 1906/4885KMT2A 4414/4885RELA 2071/4885 |
| US-20100056487-A1 | MODULATORS OF AMYLOID-BETA PRODUCTION | APP, BACE1, BACE2 | MEN1 2197/4885KMT2A 3789/4885RELA 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.